Oncotelic Therapeutics Launches AI-Powered GMP Manufacturing Platform to Address Biotech Bottleneck

Oncotelic Therapeutics (OTCQB: OTLC) has launched an artificial intelligence-powered GMP manufacturing services platform designed to address a critical bottleneck in biotechnology development: the high cost and complexity of building and maintaining compliant manufacturing infrastructure. The platform, announced in June, integrates Oncotelic's proprietary PDAOAI(TM) architecture, digital batch records, and intelligent robotics developed in partnership with TechForce Robotics.

For emerging biotechnology companies, the path from scientific discovery to clinical trials often stalls at manufacturing. Good manufacturing practices (GMP) require rigorous regulatory documentation, quality systems, process monitoring, and scalable production facilities. Smaller firms, including virtual biotechs, university spinouts, and lean startups, frequently lack the capital and expertise to build such infrastructure in-house. Oncotelic's platform targets these companies, as well as contract development and manufacturing organizations (CDMOs), cell and gene therapy developers, and radiopharmaceutical manufacturers, offering a turnkey solution without the need for substantial upfront investment.

The platform leverages AI to optimize manufacturing processes, reduce errors, and ensure compliance with regulatory standards. By digitizing batch records and incorporating intelligent robotics, it aims to improve efficiency and reproducibility in production. Oncotelic has already deployed these AI-GMP capabilities at its SAPU manufacturing base, indicating that the platform is operational and scalable. The company positions the launch not only as a pipeline accelerator for its own drug development programs but also as a potential new revenue line by offering manufacturing services to external partners.

This move comes as the biopharmaceutical industry faces increasing pressure to accelerate development timelines while managing costs. The integration of AI and robotics into GMP manufacturing is part of a broader trend toward digitalization and automation in the sector. Oncotelic's platform could help smaller players navigate regulatory complexities and bring therapies to market more efficiently. For more information about Oncotelic and its platform, visit the company's newsroom at https://ibn.fm/OTLC.